Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients

Mar 15 2021

Originally Posted in medRxiv

Jul 3 2020

Abstract: Intensive Care Unit (ICU) admissions and mortality in severe COVID-19 patients are driven by “cytokine storms” and acute respiratory distress syndrome (ARDS). Interim clinical trial results suggest that the corticosteroid dexamethasone displays superior 28-day survival in severe COVID-19 patients requiring ventilation or oxygen. Among 16 patients with plasma IL-6 measurement post-corticosteroid administration, a higher proportion of patients with an IL-6 value over 10 pg/mL have worse outcomes (i.e. ICU Length of Stay > 15 days or death) when compared to 41 patients treated with non-corticosteroid drugs including antivirals, tocilizumab, azithromycin, and hydroxychloroquine (p-value = 0.0024). Given this unexpected clinical association between post-corticosteroid IL-6 levels and COVID-19 severity, we hypothesized that the Glucocorticoid Receptor (GR or NR3C1) may be coupled to IL-6 expression in specific cell types that govern cytokine release syndrome (CRS). Examining single cell RNA-seq data from bronchoalveolar lavage fluid of severe COVID-19 patients and nearly 2 million human cells from a pan-tissue scan shows that alveolar macrophages, smooth muscle cells, and endothelial cells co-express both NR3C1 and IL-6. The mechanism of Glucocorticoid Receptor (GR) agonists mitigating pulmonary and multi-organ inflammation in some COVID-19 patients with respiratory failure, may be in part due to their successful antagonism of IL-6 production within lung macrophages and vasculature.

 

Authors:

Samir Awasthi, Tyler Wagner, AJ Venkatakrishnan, Arjun Puranik, Matthew Hurchik, Vineet Agarwal, Ian Conrad, Christian Kirkup, Raman Arunachalan, John O'Horo, Walter Kremers, Rahul Kashyap, William Morice, II, John Halamka, Amy W. Williams, William A. Faubion Jr., Andrew D. Badley, Gregory J. Gores,Venky Soundararajan

nference, Cambridge, MA 02142, USA
nference Labs, Bengaluru, KA 560047, India
Mayo Clinic, Rochester, MN 55905, USA
Mayo Clinic Laboratories, Rochester, MN 55905, USA
Mayo Clinic Platform, Rochester, MN 55905, USA
 

Correspondence: Venky Soundararajan (venky@nference.net)

 
Affiliations:
nference-logo-publications-1
mayo-logo-3-3-Mar-05-2021-08-48-39-00-PM
mayo-clinic-laboratory-logo-vector-logo-4-1-4
Copyright:
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.